Targeted therapies for chronic inflammation. Our project explores the  use of A151 immunosuppressive oligodeoxynucleotides (ODNs) to mitigate  chronic inflammation in autoimmune and autoinflammatory diseases, including rheumatoid arthritis, psoriasis, and SLE. By targeting specific  signaling pathways involved in these diseases, A151 ODN can reduce  immune overactivity and pathological inflammation. This promising approach offers a new pathway to alleviate symptoms and potentially halt disease  progression, paving the way for more effective treatments.

03

Advancing Vaccine Platforms with Virus-Like Particles

Robust protection against viral infections and beyond. We are advancing vaccine technology using Virus-Like Particles (VLPs) to provide effective protection against viruses like SARS-CoV-2 and other significant viral threats. VLPs mimic natural viruses but are non-infective, triggering strong immune responses without the risk of disease. This research not only targets viral infections but also explores VLP applications in fighting cancer and addressing neurological disabilities, creating versatile and potent vaccine formulations for future healthcare needs.